The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)

Ruhr University of Bochum

Status: Completed

Conditions: Coronary Artery Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01796691

BOCLAplan02

[Ruhr-University Bochum] (Registry Identifier)

Details and patient eligibility

About

Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

Full description

The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Enrollment: 600 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• coronary stent implantation

Exclusion criteria

• no consent

Trial design

600 participants in 2 patient groups

Standard therapy

Description:

Antiplatelet therapy following coronary stenting without platelet function testing

Optimized antiplatelet therapy

Description:

Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder. Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)